Actively Recruiting
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Led by Pfizer · Updated on 2025-12-09
1100
Participants Needed
1
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: 1. Are patients with moderate to severe AD who have been waiting to start treatment with Cibinqo 2. Have evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s) or legal guardian, have been informed of all important details of the study Investigators will collect and record the information on each participant's experiences with Cibinqo. This study medicine is a tablet which is taken by mouth. Participants will be observed for about a year. During this time, we will study the experiences of people receiving the study medicine to help us decide if the study medicine is safe and effective.
CONDITIONS
Official Title
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with moderate to severe atopic dermatitis who are starting treatment with Cibinqo Tablet according to approved indications
- Patients aged 12 years and older
- Signed and dated informed consent document from the patient or parent/legal guardian
You will not qualify if you...
- Patients who have previously received Cibinqo Tablet
- Patients currently participating in other studies involving therapeutic interventions or investigational products
- Patients with contraindications to Cibinqo Tablet, including platelet count less than 150 x 10^3/mm3, absolute neutrophil count less than 1 x 10^3/mm3, absolute lymphocyte count less than 0.5 x 10^3/mm3, or hemoglobin less than 8 g/dL
- Hypersensitivity to the active substance or excipients
- Active serious systemic infections, including tuberculosis
- Severe liver impairment
- Pregnancy or breastfeeding
- Patients with rare hereditary problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pfizer Tower
Seoul, South Korea, 04631
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here